Advaxis, Inc.

458 articles with Advaxis, Inc.

• New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies

  7/15/2019

  ADXS-NEO is a personalized immunotherapy that is designed to help a patient’s immune system recognize and respond to mutation-derived tumor antigens, or neoantigens, that are unique to his or her tumor.

• Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study

  6/27/2019

  Advaxis, Inc. announced that it is increasing its focus on neoantigen-directed immunotherapies and closing the AIM2CERV Phase 3 clinical trial with axalimogene filolisbac in high-risk locally advanced cervical cancer.

• Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update

  6/10/2019

  Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results for the fiscal second quarter ended April 30, 2019.

• Advaxis to Host Business Update Conference Call on June 11, 2019

  6/4/2019

  Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the company will host a business update call on Tuesday, June 11, 2019 at 11:00 a.m. ET.

• FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac

  5/15/2019

  Advaxis, Inc. announced that the U.S. Food and Drug Administration has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac for the treatment of patients with high-risk locally advanced cervical cancer.

• Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference

  5/14/2019

  Updated data from Phase 1/2 ADXS-PSA study combination arm show prolonged survival in heavily pretreated prostate cancer patients with microsatellite-stable (MSS) disease

• Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer

  5/13/2019

  Advaxis, Inc. (NASDAQ:ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at the end of the month.

• Advaxis to Participate in Five Upcoming Industry Conferences

  5/7/2019

  Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in five upcoming industry conferences:

• Advaxis Announces Pricing of Its Public Offering of Common Stock

  4/3/2019

  Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $4.00 per share.

• Advaxis, Inc. Announces Proposed Public Offering of Common Stock - April 2, 2019

  4/2/2019

  Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced that it intends to offer and sell in an underwritten public offering shares of its common stock.

• ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

  4/1/2019

  Updated Results from Phase 1/2 Study to be Presented Today at the AACR Annual Meeting

• Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

  3/29/2019

  Advaxis, Inc. announces the presentation of ADXS-NEO data in a poster discussion entitled “Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research (AACR) Annual Meeting underway in Atlanta.

• Advaxis Announces Reverse Stock Split

  3/28/2019

  Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its Board of Directors has approved a one-for-fifteen (1-for-15) reverse stock split of its common stock that will become effective tomorrow, March 29, 2019, upon the filing of a Certificate of Amendment to its Certificate of Incorporation with the Secretary of the State of Delaware.

• Advaxis Granted U.S. Patent Relating to Axalimogene Filolisbac

  3/25/2019

  Currently in a Phase 3 Pivotal Study for High-Risk Locally Advanced Cervical Cancer

• Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer

  2/14/2019

  To date, more than 10 drug candidates have been designed for different tumor types under the ADXS-HOT program.

• Advaxis to Present an Overview of its Lm Platform and New Information on its Neoantigen-Directed Therapy Programs at the Immuno-Oncology 360° Conference

  1/28/2019

  Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that an overview of the Company’s proprietary Lm platform and new information regarding the Company’s neoantigen-directed therapy programs, ADXS-NEO (customized, personalized neoantigens) and ADXS-HOT

• Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines

  1/25/2019

  Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell responses to a large percentage of neoantigens and to promote antigen spreading and potentially slow progression of prostate cancer, were presented at the 2019 Keystone Symposia on Cancer Vaccines,

• 

  FDA Places Advaxis Cervical Cancer Trial on Clinical Hold

  1/24/2019

  No safety issues were cited. Instead, it appears related to the company’s proposal to modify the trial’s analysis plan and various chemistry, manufacturing and controls (CMC) issues.

• Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests

  1/23/2019

  Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.S. Food and Drug Administration (FDA) that the Company’s ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV) has been placed on partial clinical hold.

• Advaxis Reports Fiscal Year 2018 Financial Results and Provides a Business Update

  1/10/2019

  Advaxis, Inc. (NASDAQ: ADXS) (the Company), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2018 and provides a business update.